SCHEMBL6014873

SCHEMBL6014873

COc1ccccc1-c1cc(-c2ccccn2)c(=O)n(-c2ccccc2Br)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 2/20 0.45
FABP3 P05413 2/20 0.41
GRM5 P41594 2/20 0.41
KDM4E B2RXH2 4/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
TACR3 P29371 1/20 0.38
POLB P06746 2/20 0.37
ALDH1A1 P00352 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28775311 0.91 DCTPP1 (0.45) DCTPP1FABP3GRM5KDM4EGAA
SCHEMBL6014953 0.85 HTR7 (0.44) FABP3KDM4ESMN1; SMN2ALDH1A1
SCHEMBL6014957 0.84 PDCD1 (0.51) DCTPP1FABP3GRM5KDM4EGAA
SCHEMBL6014946 0.84 DCTPP1 (0.39) DCTPP1GRM5KDM1AHDAC1HDAC6
SCHEMBL27755586 0.82 LMNA (0.48) DCTPP1GRM5GAASMN1; SMN2NPC1
SCHEMBL27755579 0.81 GRM5 (0.38) DCTPP1FABP3GRM5SMN1; SMN2NPC1
SCHEMBL6014907 0.79 GABRG2 (0.48) DCTPP1GAASMN1; SMN2NPC1PKM
SCHEMBL6014849 0.78 MEN1 (0.48) DCTPP1GRM5GAASMN1; SMN2NPC1
SCHEMBL6014851 0.77 HTR7 (0.44) FABP3KDM4ESMN1; SMN2RAB9AALDH1A1
SCHEMBL6014843 0.76 DCTPP1 (0.40) DCTPP1GRM5KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1319659-A1 PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF Eisai Co., Ltd. (JP) 2003-06-18 EP claimed
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-08-24 US disclosed
US-20030225081-A1 Pyridazinones and triazinones and medicinal use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-12-04 US disclosed
EP-1319659-A1 PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF Eisai Co., Ltd. (JP) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225081-A1 Pyridazinones and triazinones and medicinal use thereof GRIK1, GRIK3, GRIK2 DCTPP1 4878/4885FABP3 3260/4885GRM5 19/4885
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations GRIK3, GRIK1, GRIK2 DCTPP1 4876/4885FABP3 4050/4885GRM5 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.